Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting
Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company, has announced its 2025 Annual Stockholders Meeting will be held on November 7, 2025. The specific time and location will be detailed in the company's definitive proxy statement to be filed with the SEC.
Due to the meeting date change of more than 30 days from the 2024 annual meeting anniversary, stockholder proposals under Rule 14a-8 must be submitted by 5:00 p.m. (Central Time) on August 15, 2025. For stockholder proposals and director nominations under the company's bylaws, submissions must be received between July 10, 2025, and August 9, 2025 at the company's Huntsville, Alabama headquarters.
Serina Therapeutics (NYSE American: SER), una società biotecnologica in fase clinica, ha annunciato che la sua Assemblea Annuale degli Azionisti 2025 si terrà il 7 novembre 2025. L'orario e la sede specifici saranno indicati nel prospetto definitivo che la società presenterà alla SEC.
Poiché la data dell'assemblea è stata posticipata di oltre 30 giorni rispetto all'anniversario dell'assemblea 2024, le proposte degli azionisti ai sensi della Regola 14a-8 devono essere presentate entro le 17:00 (ora centrale) del 15 agosto 2025. Per le proposte degli azionisti e le candidature per il consiglio di amministrazione secondo lo statuto della società, le sottoscrizioni devono essere ricevute tra il 10 luglio 2025 e il 9 agosto 2025 presso la sede di Huntsville, Alabama.
Serina Therapeutics (NYSE American: SER), una empresa biotecnológica en etapa clínica, ha anunciado que su Junta Anual de Accionistas 2025 se llevará a cabo el 7 de noviembre de 2025. La hora y el lugar específicos se detallarán en la declaración definitiva de poder que la compañía presentará ante la SEC.
Dado que la fecha de la junta se ha cambiado en más de 30 días respecto al aniversario de la junta anual de 2024, las propuestas de los accionistas bajo la Regla 14a-8 deben presentarse antes de las 5:00 p.m. (hora central) del 15 de agosto de 2025. Para propuestas de accionistas y nominaciones de directores bajo los estatutos de la compañía, las presentaciones deben recibirse entre el 10 de julio de 2025 y el 9 de agosto de 2025 en la sede de la compañía en Huntsville, Alabama.
Serina Therapeutics (NYSE American: SER)는 임상 단계의 생명공학 회사로, 2025년 연례 주주총회가 2025년 11월 7일에 개최될 예정임을 발표했습니다. 구체적인 시간과 장소는 회사가 SEC에 제출할 최종 위임장에 명시될 예정입니다.
2024년 연례 총회 기념일로부터 30일 이상 변경된 회의 날짜로 인해, 규칙 14a-8에 따른 주주 제안은 2025년 8월 15일 오후 5시(중부 시간)까지 제출되어야 합니다. 회사 정관에 따른 주주 제안 및 이사 후보 지명은 2025년 7월 10일부터 8월 9일 사이에 앨라배마주 헌츠빌에 위치한 본사로 접수되어야 합니다.
Serina Therapeutics (NYSE American : SER), une société de biotechnologie en phase clinique, a annoncé que son Assemblée annuelle des actionnaires 2025 se tiendra le 7 novembre 2025. L'heure et le lieu précis seront indiqués dans la déclaration de procuration définitive que la société déposera auprès de la SEC.
En raison du changement de date de l'assemblée de plus de 30 jours par rapport à l'anniversaire de l'assemblée annuelle 2024, les propositions des actionnaires conformément à la règle 14a-8 doivent être soumises avant 17h00 (heure centrale) le 15 août 2025. Pour les propositions des actionnaires et les nominations de directeurs selon les statuts de la société, les soumissions doivent être reçues entre le 10 juillet 2025 et le 9 août 2025 au siège social de la société à Huntsville, Alabama.
Serina Therapeutics (NYSE American: SER), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, hat bekannt gegeben, dass seine Jahreshauptversammlung 2025 am 7. November 2025 stattfinden wird. Die genaue Uhrzeit und der Ort werden in der endgültigen Vollmachtserklärung des Unternehmens, die bei der SEC eingereicht wird, angegeben.
Da sich das Datum der Versammlung um mehr als 30 Tage gegenüber dem Jahrestag der Hauptversammlung 2024 verschoben hat, müssen Aktionärsvorschläge gemäß Regel 14a-8 bis spätestens 15. August 2025, 17:00 Uhr (Central Time) eingereicht werden. Für Aktionärsvorschläge und Direktoren-Nominierungen gemäß der Satzung des Unternehmens müssen Einreichungen zwischen dem 10. Juli 2025 und dem 9. August 2025 am Hauptsitz des Unternehmens in Huntsville, Alabama, eingehen.
- None.
- None.
HUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the “Annual Meeting”). The time and location of the Annual Meeting will be set forth in the Serina’s definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission (the “SEC”).
Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Serina’s 2024 annual meeting of stockholders, the deadline for stockholder proposals to be submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), for inclusion in Serina’ proxy materials for the Annual Meeting will be 5:00 p.m. (Central Time) on Friday, August 15, 2025, which Serina’s Board of Directors has determined to be a reasonable period of time before Serina expects to begin to print and send its proxy materials for the Annual Meeting. Stockholder proposals submitted in accordance with Rule 14a-8 of the Exchange Act must also comply with the remaining requirements of Rule 14a-8 in order to be included in the proxy materials for the Annual Meeting.
Stockholder proposals and director nominations submitted pursuant to Serina’s Amended and Restated Bylaws for consideration at the Annual Meeting must be submitted in writing and must be received by the Corporate Secretary at Serina’s principal executive offices at Serina Therapeutics, Inc., 601 Genome Way, Suite 2001, Huntsville, Alabama 35806, no earlier than July 10, 2025, and no later than August 9, 2025, in order to be considered timely. Stockholder proposals outside of Rule 14a-8 of the Exchange Act and director nominations must also comply with the requirements contained in Section 3.2 of Serina’s Amended and Restated Bylaws in order to be considered at the Annual Meeting. Stockholders are urged to read the complete text of Serina’s Amended and Restated Bylaws for complete information regarding submission.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
For more information, please visit https://serinatherapeutics.com.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina’s Annual Report on Form 10-K for the year ended December 31, 2024, and Serina’s other periodic reports and documents filed from time to time with the SEC.
The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
